Gujarat Kidney And Super Speciality Limited
Gujarat Kidney And Super Speciality Limited (GKSL) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Healthcare Services›Hospital
gujaratsuperspecialityhospital.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 13 Cr | 23 Cr | 31 Cr | 34 Cr |
| Operating expenses (approx.) | 8 Cr | 16 Cr | 24 Cr | 26 Cr |
| EBITDA | 5 Cr | 7 Cr | 6 Cr | 8 Cr |
| OPM % | 39.6% | 29.7% | 20.6% | 24.4% |
| Other income | 0.09 Cr | 0.06 Cr | 0.71 Cr | 0.69 Cr |
| Interest | 0.28 Cr | 0.60 Cr | 0.82 Cr | 0.66 Cr |
| Depreciation | 0.90 Cr | 1 Cr | 2 Cr | 1 Cr |
| Profit before tax | 4 Cr | 5 Cr | 5 Cr | 7 Cr |
| Tax % | 28.6% | 26.3% | -3.0% | 23.6% |
| Net profit | 3 Cr | 4 Cr | 5 Cr | 5 Cr |
| EPS (₹) | ₹0.52 | ₹0.52 | ₹0.81 | ₹0.66 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 82 Cr | Sign in for TTM |
| Operating expenses (approx.) | 55 Cr | Sign in for TTM |
| EBITDA | 27 Cr | Sign in for TTM |
| OPM % | 32.8% | Sign in for TTM |
| Other income | 0.87 Cr | Sign in for TTM |
| Interest | 2 Cr | Sign in for TTM |
| Depreciation | 5 Cr | Sign in for TTM |
| Profit before tax | 21 Cr | Sign in for TTM |
| Tax % | 20.8% | Sign in for TTM |
| Net profit | 17 Cr | Sign in for TTM |
| EPS (₹) | ₹2.49 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 16 Cr |
| Reserves | 237 Cr |
| Borrowings | 16 Cr |
| Other liabilities | 27 Cr |
| Total liabilities | 298 Cr |
| Fixed assets (net) | 27 Cr |
| CWIP | — |
| Investments | 0 Cr |
| Loans & advances | 0.85 Cr |
| Inventories | 2 Cr |
| Trade receivables | 39 Cr |
| Cash & bank | 13 Cr |
| Other assets | 216 Cr |
| Total assets | 298 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | -4 Cr |
| Cash from investing | -214 Cr |
| Cash from financing | 228 Cr |
| Net cash flow | 11 Cr |
| Free cash flow (OCF − Capex) | -98 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 8.5% |
| ROE % | 6.1% |
| Debtor days | 171 |
| Inventory days | 82 |
| Days payable | 338 |
| Cash conversion cycle | -84 |
| Debt / equity | 0.06 |
| Current ratio | 3.76 |
| Net debt / EBITDA | 0.09 |
Compare with peers
Loading peers…